We propose to establish an Antibody Core at the Rockefeller University which will serve as an antibody resource for investigators participating in the ADCC. The initial focus of the Core will be to produce, store and provide antibodies relevant to the study of APP and Abeta. Much of our understanding of the processing of APP, the production of Abeta, and the formation of insoluble Abeta-amyloid has depended on experiments carried out using well-defined antibodies. Furthermore, such antibodies have also been extensively used to examine the neuropathological progression of Abeta-amyloidosis. The recent discovery of APP-related proteins which cross-react with anti-APP antibodies but are not a source of Abeta makes the development of APP-specific antibodies particularly important. We propose to prepare a large panel of monoclonal antibodies with defined properties to be used for studies of APP processing. Abeta production, and Abeta amyloidogenesis. The establishment of this Antibody Core will provide valuable support to researchers at Rockefeller, NYU, IBR and NKI who are participating in the ADCC, as well as to scientists at other ADCs. Studies using core resources will be more cost effective, and in some instances projects will be conducted that would not be feasible without the availability of these antibodies. Establishment of this Core also will strengthen the involvement of The Rockefeller University Laboratory of molecular and Cellular Neuroscience in the ADCC.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG008051-09
Application #
6267421
Study Section
Project Start
1998-07-01
Project End
1999-04-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
9
Fiscal Year
1998
Total Cost
Indirect Cost
Name
New York University
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10016
Brenowitz, Willa D; Han, Fang; Kukull, Walter A et al. (2018) Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults. Neurobiol Aging 62:64-71
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Kochunov, Peter; Dickie, Erin W; Viviano, Joseph D et al. (2018) Integration of routine QA data into mega-analysis may improve quality and sensitivity of multisite diffusion tensor imaging studies. Hum Brain Mapp 39:1015-1023
Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27
Gallagher, Damien; Kiss, Alex; Lanctot, Krista L et al. (2018) Toward Prevention of Mild Cognitive Impairment in Older Adults With Depression: An Observational Study of Potentially Modifiable Risk Factors. J Clin Psychiatry 80:
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Adhikari, Bhim M; Jahanshad, Neda; Shukla, Dinesh et al. (2018) Heritability estimates on resting state fMRI data using ENIGMA analysis pipeline. Pac Symp Biocomput 23:307-318
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Solesio, MarĂ­a E; Peixoto, Pablo M; Debure, Ludovic et al. (2018) Carbonic anhydrase inhibition selectively prevents amyloid ? neurovascular mitochondrial toxicity. Aging Cell :e12787

Showing the most recent 10 out of 604 publications